Success Stories: Surgical Pathology Fellow Investigating Molecular Cancer Mechanisms Secured NIW in Just Over a Week With NAILG

Client’s Testimonial:

“I got in touch with North America Immigration Law Group through a referral by a friend who also had a great experience. It was a wonderful experience working with them on my application. They always reply within 24 hours. They provided a high level of guidance as well as attention to detail. They suggested some extra documents based on recent trends. I am so happy for the case approval and want to thank them so much for guiding me through this path. Highly recommend them.”

On April 20^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Surgical Pathology Fellow in the Field of Pathology (Approval Notice).

General Field: Pathology

Position at the Time of Case Filing: Surgical Pathology Fellow

Country of Origin: Pakistan

State of Residence at the Time of Filing: Florida

Approval Notice Date: April 20^th, 2025

Processing Time: 9 days (Premium Processing Requested)

Case Summary:

An accomplished pathologist partnered with the North America Immigration Law Group (NAILG) to pursue a National Interest Waiver (NIW) petition based on his groundbreaking work in cancer diagnostics. From the outset, NAILG recognized the national health relevance of his research, which focuses on the advanced histologic, immunologic, and molecular characteristics of malignant tissues, particularly in breast, renal, gastrointestinal, and hematolymphoid neoplasms. Together, they developed a legal strategy that showcased how our client’s research addresses one of the nation’s most urgent challenges: improving early detection and treatment planning for common and often deadly cancers.

His proposed endeavor aims to elevate the accuracy of pathology-based diagnostics using cutting-edge laboratory techniques. By investigating cancer tissues at the molecular level, his research enhances diagnostic precision, supports the discovery of novel treatment strategies, and contributes to early disease detection – a key to improving patient survival. NAILG underscored how his work supports the U.S. healthcare system’s ongoing efforts to reduce cancer burden through innovation in detection and diagnosis.

Our client’s scientific credentials were a core component of the petition. His contributions include 12 peer-reviewed journal articles, 6 abstracts (including 2 first-authored), and 1 book chapter, with his published work having been cited 113 times. He has also served as a peer reviewer for at least 6 academic submissions, further demonstrating his recognition and active participation in the pathology research community.

A letter submitted in support of his petition highlighted the clinical value of his research:

“As a conclusion, [client]’s leadership in pathology is evident with his contributions to breast cancer treatment, particularly through his insights into the impact of TILs on patient survival. There is no doubt that [client] will continue to produce valuable research that drives progress in the field and brings significant benefits to both national and international healthcare.”

Throughout the petition process, NAILG played a critical role in shaping and presenting the evidence to meet USCIS’s standards under the Matter of Dhanasar framework. By emphasizing the substantial merit, national importance, and the clear benefit of waiving labor certification, NAILG successfully secured NIW approval for our client. He is now well-positioned to continue his impactful research in the United States, where his contributions will further enhance cancer diagnostics and patient outcomes nationwide.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.